This is an automatically translated article.
Loraar 50 contains the active ingredient Losartan potassium 50mg, indicated in the treatment of mild to moderate hypertension... Let's learn about the uses and notes when using Loraar 50 through the article below.
1. What is Loraar 50?
Loraar 50 is prepared in the form of film-coated tablets containing 50mg of Losartan potassium. Losartan is an active ingredient in a new class of antihypertensive drugs - specific Angiotensin II receptor antagonists. Angiotensin II belongs to the group of vasoconstrictors and has activity mainly on the Renin - Angiotensin - Aldosterone system, which plays an important role in the pathophysiology of hypertension. The metabolite of Losartan has selective antagonistic activity on the vasoconstriction and aldosterone secretion of Angiotensin II through a mechanism that selectively blocks the binding of Angiotensin II to the AT receptor.
Loraar 50 is indicated alone or in combination with other drugs in the treatment of mild to moderate hypertension, especially in patients experiencing dry cough due to treatment with ACE inhibitors. .
2. Dosage of Loraar 50
Dosage of Loraar 50 is prescribed by the treating doctor based on the patient's condition. Some recommendations on the dosage of Loraar 50 are as follows:
The starting dose in adults is 50mg/day, the dose can be increased to 100mg/day orally once or divided into 2 doses; For the elderly should use a lower dose, about 25mg / day in patients over 75 years old, patients with moderate to severe hepatic or renal impairment, patients with loss of intravascular fluid. Loraar 50 can be taken with or without food.
3. Side effects of the drug Loraar 50
Loraar 50 may cause some unwanted effects as follows:
Common: Insomnia, hypotension, dizziness, hyperkalemia, dyspepsia, diarrhea, low hematocrit and blood hemoglobin, leg pain , back pain, muscle pain, hypouricemia (when taking high doses), nasal congestion, cough, sinusitis ; Uncommon: Orthostatic hypotension, grade II A-V block, sinus bradycardia, tachycardia, facial flushing, facial edema, ataxia, anxiety, depression, confusion, sleep disturbance, dizziness face, fever, dermatitis, alopecia, erythema, photosensitivity, urticaria, rash, bruises, gout, constipation, loss of appetite, gastritis, loss of taste, decreased libido sex drive, impotence, nocturia, polyuria, slight increase in liver function tests, mild hyperbilirubinemia, decreased visual acuity, burning and stinging eyes, tinnitus, slight increase in creatinine, urinary tract infection, inflammation bronchi, dyspnea, epistaxis, airway congestion, throat discomfort. Patients need to stop using Loraar 50 and notify the treating doctor in case of any unwanted effects.
4. Notes when using Loraar 50
4.1. Contraindications Loraar 50 is contraindicated to use Loraar 50 in the following cases:
Patients with hypersensitivity to Losartan or any of its ingredients; Pregnant women; Contraindicated in combination with potassium-sparing diuretics. 4.2. Precautions while using Loraar 50 Use caution when using Loraar 50 in patients with renal artery stenosis, liver or kidney failure.
Patients with intravascular volume depletion as being treated with high-dose diuretics may lead to hypotension during treatment with Loraar 50. Therefore, patients should be corrected for this condition before taking Losartan.
Hyperkalemia may occur, so patients need to control serum potassium levels, especially in elderly patients, patients with renal impairment and avoid concomitant use with potassium-sparing diuretics.
The safety of Loraar 50 has not been established in children, so do not use Loraar 50 in children without consulting a doctor.
5. Drug interactions
The antihypertensive effect of Losartan is increased when used concomitantly with other antihypertensive agents. Concurrent use of Losartan and drugs that increase blood potassium levels such as potassium-sparing diuretics, potassium-containing supplements, etc. may increase blood pressure. The active ingredient Losartan in Loraar 50 is metabolised by cytochrome P450 enzymes and affects the metabolism of several drugs metabolised by these enzymes. Losartan AUC increased by approximately 1.8% when co-administered with Cimetidine. The plasma concentrations of losartan and its active metabolite are decreased when co-administered with phenobarbital. Ketoconazole inhibits the conversion of losartan to the active substance. Drug interactions may occur that increase the risk of effects and reduce the treatment effect of Loraar 50, so to ensure safety and effectiveness in treating patients, it is necessary to inform the doctor about the drugs, food being used before taking Loraar 50.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
